August 2018

Aurora-Garg #NGDx18 Keytruda: PL-L1 ligand implicated w/immune escape with HNSCC; both tumor and immune cells overexp PDL1 and PDL2.

8:48am August 21st 2018 via Twitter Web Client

Aurora-Garg #NGDx18 Head and Neck: lip, oral cavity, pharynx, larynx, or paranasal sinuses. 3-5% of all cancers; 55K diagnosed in '17 US

8:43am August 21st 2018 via Twitter Web Client

Aurora-Garg #NGDx18 Tumor cells, NK cells, macrophages, CD8 T cells, Dendritic cells, fibroblasts, CD4 T-cells, all interact

8:41am August 21st 2018 via Twitter Web Client

Aurora-Garg #NGDx18 '08 first PhI anti-PD1 clin trial; '11 first FDA approval anti-CTLA4 (ipi); '14 first anti-PD1 (nivo) approved

8:37am August 21st 2018 via Twitter Web Client

Consumer genomics will change your life, whether you get tested or not | Genome Biology https://t.co/7Aji5ZvxI7

8:15pm August 20th 2018 via Hootsuite Inc.

Lichtenfeld #NGDx18 With 21% responding, that is up from 0%. Yet getting EGFR testing done broadly, that is still a challenge.

5:28pm August 20th 2018 via Twitter Web Client

Lichtenfeld #NGDx18 The world is changing; the disruptors are changing the cost structure. 'Lower cost somewhere else.'

5:13pm August 20th 2018 via Twitter Web Client

Pratt #NGDx18 Other NGS testing was reimb so low she shut it down and sends it out instead.

5:10pm August 20th 2018 via Twitter Web Client

Lichtenfeld #NGDx18 We have a long way to go... QALY valued at $36K in the UK? Here is $50K-$100K for QALY. Will it improve outcomes?

5:07pm August 20th 2018 via Twitter Web Client

Lichtenfeld #NGDx18 But part of the battle: when do you find signal in cfDNA, and what really makes a difference in the outcome?

5:06pm August 20th 2018 via Twitter Web Client

Lichtenfeld #NGDx18 We will need to understand what works, what doesn't. cfDNA: is now moving into early-det phase.

5:06pm August 20th 2018 via Twitter Web Client

Dietzen #NGDx18 Value is not (always) single-test, single-outcome. Life-saving many times.

5:00pm August 20th 2018 via Twitter Web Client

Leite #NGDx18 CDx may be viewed as a restriction of the market; for Loxo, viewed as an expansion, for multi-gene testing.

4:58pm August 20th 2018 via Twitter Web Client

Leite #NGDx18 Clinicians in China has physicians much more value-based in their thinking (may be due to self-payer situation)

4:56pm August 20th 2018 via Twitter Web Client

Van Meter #NGDx18 Now is moving toward value for public health issues (antibiotic resistance for example)

4:52pm August 20th 2018 via Twitter Web Client

Van Meter #NGDx18: @AdvaMedDx developed a model of value-based metrics, to both Pts and physicians, also value of speed of test

4:51pm August 20th 2018 via Twitter Web Client

Van Meter: @AdvaMedDx developed a model of value-based metrics, to both the pt and physician; also speed of the test

4:50pm August 20th 2018 via Twitter Web Client

Cecilia Schott (AstraZeneca) moderator for #NGDx18 panel; Dennis Dietzen (WashU); John Leite (Illumina); Leonard Lichtenfeld (ACS);

4:39pm August 20th 2018 via Twitter Web Client

Dietzen #NGDx18 Reimb. has historically been cost-based; but what is the value? Accountible care?

4:36pm August 20th 2018 via Twitter Web Client

Dietzen #NGDx18 Increasing test volume, cost; PAMA/novel coding; demand for clin utility evidence; value-based care

4:34pm August 20th 2018 via Twitter Web Client

Dietzen #NGDx18 "Theranos was literally a black box; make it any color except for black, please!"

4:30pm August 20th 2018 via Twitter Web Client

Dietzen #NGDx18 Opportunities: LDT vs IVD, new FDA pathwasy, EQA. Challenges - lack of transparency, 'Bad Actors', EU IVD directives

4:30pm August 20th 2018 via Twitter Web Client

Plenary panel at #NGDx18 Policy and prediction for diagnostics. Dennis Dietzen (President of AACC, WashU)

4:27pm August 20th 2018 via Twitter Web Client

Jia #NGDx18 Plans to go beyond blood to urine. Other two tests: ATLAS, (600 gene panel for TMB), Hereditary, 25-gene incl BRCA.

3:31pm August 20th 2018 via Twitter Web Client

Jia #NGDx18 Shows CNA data from cfDNA of AR gene.

3:28pm August 20th 2018 via Twitter Web Client

Jia #NGDx18 Difference in var calls between RNA and DNA: AR AF starts at zero, goes up post-Rx.

3:22pm August 20th 2018 via Twitter Web Client

Jia #NGDx18 Shows AR-V7 MOA in metastatic colorectal prostate cancer over course of Rx, relapse by PSA level

3:21pm August 20th 2018 via Twitter Web Client

Jia #NGDx18 Able to pick up ctDNA based detection of MET exon skipping; also AR-V7 splicing variants.

3:20pm August 20th 2018 via Twitter Web Client

Jia #NGDx18 RNA splicing, fusions; DNA shows PPV 93.0%. Shows RNA + DNA increasing sens down to 0.06% AF.

3:18pm August 20th 2018 via Twitter Web Client

Jia #NGDx18 Have 5 tests: DDR (DNA damage repair 15 genes), LITE (pan cancer 81 genes), RNA fusions, two others.

3:12pm August 20th 2018 via Twitter Web Client

Jia #NGDx18 Founded '15, CLIA/CAP, clobalpresence, GeneRADAR liquid biopsy tech.

3:12pm August 20th 2018 via Twitter Web Client

Shidong Jia (Predicine) Transforming immuno-oncology with ctRNA + ctDNA liquid biopsy solutions #NGDx18

3:11pm August 20th 2018 via Twitter Web Client

Bresler #NGDx18 Found loss of reagent on side of vessel. Only when vessel was open, and temperature fluctuation on-instrument.

2:58pm August 20th 2018 via Twitter Web Client

Bresler #NGDx18 'Dealing with foreseeable misuse.' Want multi-organism panels, smartphone capable, and simple.

2:57pm August 20th 2018 via Twitter Web Client

Bresler #NGDx18 New tech: RF transmitters / receivers to sense sub-cutaneous fat vs injected fluid, and tunable.

2:53pm August 20th 2018 via Twitter Web Client

Bresler #NGDx18 CT scans may have contrast media injections. Want to prevent extravasation - contrast agent leaking into tissue.

2:52pm August 20th 2018 via Twitter Web Client

Bresler #NGDx18 Put a Sharpie 'dot' for the abnormal sites for prior workflow - so they designed a Sharpie to fit the instrument (!)

2:50pm August 20th 2018 via Twitter Web Client